Skip to main content

Bionano Genomics Announces Presentations on Optical Genome Mapping at the American Association for Cancer Research (AACR) Annual Meeting 2021

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that multiple studies on the detection of structural variants using Bionano’s optical genome mapping, including a Spotlight Presentation, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which is being held in a virtual format April 10-15, 2021.

Details of the presentations are as follows:

Title of Spotlight Presentation: “Optical Genome Mapping: Unrivaled Structural Variant Detection for Cancer Research and Precision Medicine” – Dr. Yannick Delpu, Bionano Genomics
“Optical Genome Mapping Uncovers Novel Structural Variants Associated With Drug Sensitivities In Leukemias” – Dr. Darren Finlay, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
Presentation Time: April 14, 2021, 1:00 – 2:00 PM EDT
Session Category: ESP.15

Title: Detection of Structural Variation and Analysis on HuKemia Models by Using Bionano Optical Mapping
Session Category: Molecular and Cellular Biology/Genetics
Session Title: Genomic Profiling of Tumors
Permanent Abstract Number: 2234
Authors: Xiaobo Chen, Huan Tian, Wubin Qian, Henry Q. Li, Sheng Guo. Crown Bioscience Inc, Suzhou, China, Crown Bioscience Inc, San Diego, CA

More details can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2021/.

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations and
Media Contact:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.